Gofen & Glossberg’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$858K Buy
2,970
+74
+3% +$22.6K 0.02% 262
2022
Q3
$839K Buy
2,896
+8
+0.3% +$2.3K 0.02% 245
2022
Q2
$814K Sell
2,888
-206
-7% -$55.1K 0.02% 252
2022
Q1
$807K Hold
3,094
0.02% 262
2021
Q4
$679K Sell
3,094
-31
-1% -$6.03K 0.01% 301
2021
Q3
$567K Buy
3,125
+31
+1% +$6.05K 0.01% 320
2021
Q2
$624K Sell
3,094
-326
-10% -$68.2K 0.01% 302
2021
Q1
$735K Sell
3,420
-35
-1% -$7.69K 0.02% 273
2020
Q4
$817K Sell
3,455
-42
-1% -$9.64K 0.02% 252
2020
Q3
$952K Buy
3,497
+206
+6% +$56.8K 0.03% 224
2020
Q2
$955K Hold
3,291
0.03% 214
2020
Q1
$783K Buy
3,291
+13
+0.4% +$2.98K 0.03% 215
2019
Q4
$718K Sell
3,278
-74
-2% -$15K 0.02% 249
2019
Q3
$568K Buy
3,352
+42
+1% +$7.43K 0.02% 272
2019
Q2
$607K Hold
3,310
0.02% 261
2019
Q1
$609K Hold
3,310
0.02% 249
2018
Q4
$549K Hold
3,310
0.02% 251
2018
Q3
$638K Hold
3,310
0.02% 252
2018
Q2
$563K Hold
3,310
0.02% 261
2018
Q1
$539K Hold
3,310
0.02% 269
2017
Q4
$496K Hold
3,310
0.02% 299
2017
Q3
$503K Hold
3,310
0.02% 288
2017
Q2
$427K Sell
3,310
-50
-1% -$6.02K 0.02% 313
2017
Q1
$367K Sell
3,360
-39
-1% -$3.43K 0.01% 335
2016
Q4
$250K Hold
3,399
0.01% 378
2016
Q3
$296K Hold
3,399
0.01% 353
2016
Q2
$292K Sell
3,399
-202
-6% -$17.5K 0.01% 356
2016
Q1
$286K Buy
3,601
+91
+3% +$8.23K 0.01% 357
2015
Q4
$442K Buy
3,510
+300
+9% +$36.2K 0.02% 290
2015
Q3
$334K Buy
3,210
+25
+0.8% +$3.21K 0.02% 322
2015
Q2
$393K Hold
3,185
0.02% 309
2015
Q1
$376K Hold
3,185
0.02% 319
2014
Q4
$378K Buy
3,185
+35
+1% +$3.94K 0.02% 315
2014
Q3
$354K Hold
3,150
0.02% 315
2014
Q2
$298K Sell
3,150
-950
-23% -$66.6K 0.01% 347
2014
Q1
$332K Hold
4,100
0.02% 324
2013
Q4
$305K Sell
4,100
-200
-5% -$13.9K 0.01% 335
2013
Q3
$326K Hold
4,300
0.02% 309
2013
Q2
$344K Buy
+4,300
New +$317K 0.02% 290

Other funds holding VRTX

Gofen & Glossberg's VRTX Position: Q4 2022 in Review

Gofen & Glossberg increased its Vertex Pharmaceuticals (VRTX) stake by 2.6% in Q4 2022, buying an estimated $22.6K and bringing the position to 2,970 shares worth $858K. The position accounts for 0.02% of the portfolio, ranked #262.

Gofen & Glossberg first reported a position in VRTX in Q2 2013 and has held it in 39 quarters since. The position peaked at $955K in Q2 2020. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

  • Gofen & Glossberg held 2,970 shares of Vertex Pharmaceuticals worth $858K as of Q4 2022.
  • Gofen & Glossberg bought 74 Vertex Pharmaceuticals shares in Q4 2022, an estimated $22.6K.
  • Vertex Pharmaceuticals made up 0.02% of Gofen & Glossberg's portfolio in Q4 2022, its #262 holding.
  • Gofen & Glossberg first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 39 quarters since.
  • Gofen & Glossberg's Vertex Pharmaceuticals position peaked at $955K in Q2 2020.
  • 1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Gofen & Glossberg's 13F filing for Q4 2022, filed 13 Jan 2023.